Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2025-11-14 00:00:00 ET · period of report 2025-11-12 · accession 0001951238-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-11-14 | 2025-11-12 | SPRY | Chakma Justin | Chief Business Off | S - Sale+OE | $8.87 | -166.4K | 136.4K | -55% | -$1.48M |
| D | 2025-11-14 | 2025-11-12 | SPRY | Chakma Justin | Chief Business Off | M - OptEx | $0.84 | +30.0K | 166.4K | +22% | +$25.2K |
| D | 2025-11-14 | 2025-11-12 | SPRY | Chakma Justin | Chief Business Off | M - OptEx | $0.00 | -30.0K | 89.0K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-12 | S | D | 136,380 | $8.86 | 0 | D | — | — | (F2) The weighted average sale price for the transaction reported was $8.8634, and the range of prices was between $8.62 and $9.04. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 2 | Common | Common Stock | 2025-11-12 | S | D | 30,000 | $8.91 | 136,380 | D | — | — | (F1) The weighted average sale price for the transaction reported was $8.9119, and the range of prices was between $8.87 and $8.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 3 | Common | Common Stock | 2025-11-12 | M | A | 30,000 | $0.84 | 166,380 | D | — | — | |
| 4 | Derivative | Stock Option (Right to Buy) | 2025-11-12 | M | D | 30,000 | $0.00 | 89,047 | D | $0.84 · — to 2029-07-04 | 30,000 Common Stock | (F3) Immediately exercisable. |